Buscar
Congreso SOLACI
HomeInternational CongressesESC 2017

ESC 2017

Ver Categoría
Chronic Ischemic cardiopathy

SYNTAX II: Better Stents, IVUS, FFR, or a Combination of All of Them to Catch Up with Surgery

In patients with 3-vessel disease, surgery obtained better outcomes than angioplasty, according to results from the SYNTAX...
solaci -
Ver más
HIGHLIGHTS

FOURIER: Efficacy of Evolocumab for Ultra-Low LDL Levels

It seems that a LDL level of 70 mg/dL is no longer low enough for high-risk secondary patients;...
solaci -
Ver más
Acute coronary syndromes

DETO2X-AMI: Supplemental O2 Provides No Benefit for Patients with Suspected Infarction

According to this study simultaneously presented at the European Society of Cardiology Congress 2017 and published in...
solaci -
Ver más
Antithrombotic Anticoagulants

COMPASS: A New Place for Rivaroxaban in Chronic Ischemic Heart Disease

Combining low doses of rivaroxaban and aspirin seems to be the best strategy for patients with stable...
solaci -
Ver más
HIGHLIGHTS

CANTOS: Anti-inflammatory Drug Canakinumab Seems to Reduce CV Events

This human monoclonal antibody that specifically targets inflammatory cells seems to reduce cardiovascular events when associated with...
solaci -
Ver más
Acute coronary syndromes

VALIDATE-SWEDEHEART: bivalirudin seems to be losing ground

Another important work that does not see the benefits of bivalirudin over heparin as monotherapy as regards both...
solaci -
Ver más
HIGHLIGHTS

SPYRAL HTN-OFF MED: Renal Denervation Reloaded?

This work presented at the ESC Congress 2017 held in Barcelona, simultaneously published in The Lancet, seems to...
solaci -
Ver más
Antithrombotic Anticoagulants

RE-DUAL PCI: Anti-Thrombotic Management in Patients with Atrial Fibrillation and PCI

RE-DUAL PCI outcomes have been published by the  New England Journal of Medicine along with their presentation at...
solaci -
Ver más

SOLACI es la organización de referencia del intervencionismo cardiovascular latinoamericano.

Últimas Noticias

TCT 2024 | FAVOR III EUROPA

Dr. Carlos Fava - 0
The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

Dr. Carlos Fava - 0
This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Dr. Omar Tupayachi - 0
Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

Noticias Institucionales

The El Salvador 2024 Sessions are coming soon

solaci - 0
The XLIX SOLACI 2024 Regional Sessions (17th Central America & the Caribbean) are approaching, and will take place in the city of San Salvador (El Salvador)....

Check out the best images of the Arequipa 2024 Sessions

solaci - 0
Review the highlights of the XVIII SOLACI Regional Sessions held at the Hanan Hotel in Arequipa, Peru between October 3 and 4, 2024. <!-- wp:tw/bwg...

Arequipa Sessions 2024: Meet the International Guests

solaci - 0
The Arequipa Sessions 2024 is getting closer and closer. Meet the international guests who will share their knowledge for 2 days at a high-level...

Accesos

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Términos de uso -Políticas de privacidad